Business
Ventripoint Diagnostics Announces Appointment of David Swetlow as Chief Financial Officer
(TheNewswire) New CFO appointment strengthens Ventripoint’s leadership team and supp...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Diagnostics Announces Appointment of David Swetlow as Chief Financial Officer\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n New CFO appointment strengthens\nVentripoint’s leadership team and supports global rollout of\nAI-powered VMS+™ cardiac imaging platform.\n \n\n\n\n Toronto, Ontario –\n \n\n TheNewswire -\n \n\n December 3, 2025\n \n\n -\nVentripoint Diagnostics Ltd.\n \n\n (\"\n \n\n Ventripoint\n \n\n \",\n“\n \n\n VPT\n \n\n ” or the \"\n \n\n Company\n \n\n \"), (TSXV:VPT; OTC:VPTDF) a leader\nin AI-enhanced cardiac imaging solutions, today announced the\nappointment of David Swetlow, CPA, CA, iGP as Chief Financial Officer\n(“\n \n\n CFO\n \n\n ”), effective immediately.\n \n\n This\nappointment represents an important step in strengthening\nVentripoint’s leadership team as the Company embarks on its new\ncommercial strategic vision and transitions into its growth\nphase.\n \n\n\n\n Mr. Swetlow brings extensive senior management,\nfinancial and public company leadership experience from various roles\nacross high-growth medical technology and innovative life science\ncompanies, including Sernova, Ondine, Protox, HealthPricer, One Person\nHealth, QLT and Xillix, with a track record of building and executing\nrobust capital markets strategies; company scale up, product launch\nand commercialization strategies success; driving and evolving\nfinancial systems, reporting, and operational performance for next\nstage growth; strategic relationship management; and enhancing\ncorporate governance. His broad expertise will be instrumental to\npositioning VPT to achieve the next stage of VMS+ platform market\nadoption success and expansion abroad.\n \n\n\n\n “This is a pivotal moment for Ventripoint,” said\nHugh MacNaught, President & CEO of Ventripoint Diagnostics.\n“David’s leadership will play a vital role as we execute on a\nrefreshed commercial strategy designed to scale our technology and\nplatform, strengthen our global partnerships, and position the company\nfor new markets and revenue growth.\n \n\n\n\n As Ventripoint moves into this next stage, the Company\nalso extends its appreciation to Jimmy Jeon, who has resigned as CFO\nand Marelli Services for their valuabl...